MLAB logo

MESA LABORATORIES INC

MLABNASDAQ
πŸ† #2693 by market capEarnings Nov 4US Equity
$237.28β–² $7.09 (+2.99%)
Simulated price
πŸ””
Track MLAB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.0%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$750M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+3.4%
Slowing
πŸ“ŠGross Margin
66.0%
High
πŸ’΅FCF Margin
22.5%
Strong
βš–οΈP/S Ratio
3.0x
Fair
Otter Score
60
Fair
No chart data available for MLAB.

Trading Snapshot

Day Range
$235.45 – $239.55
52-Week Range
$63.48 – $138.66
Volume
$1.83B
Avg Volume
$1.73B
Shares Outstanding
5.6M
Next Earnings
Dec 15, 2026

Fundamentals Snapshot

Annual Revenue
$249M
Last Q Revenue
$60M
P/E Ratio
155.9
P/S Ratio
3.0x
EPS (TTM)
$0.85
Dividend Yield
0.48%
Dilution (1yr)
+3.5%

Why Investors Own MLAB

  • βœ“High-growth profile β€” revenue up +38.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 53% gross margin and 22% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MLAB logo

MESA LABORATORIES INC

MLAB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$249Mβ–² +3.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
63.5%β–² +1.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$19Mβ–² +13.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$40Mβ–Ό βˆ’6.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.8Mβ–² +3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$71Mβ–² +$81M YoY
StockOtter Β· stockotter.space

About MESA LABORATORIES INC

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy3
Buy3
Hold3
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates